Aeolus Pharmaceuticals Inc. (OTCPK:AOLS) announced a private placement of 6% convertible promissory notes for gross proceeds of $1,000,000 with existing investor Biotechnology Value Fund L.P., a fund managed by BVF Partners LP on September 29, 2015. The note carries a fixed interest rate of 6% per annum and would mature September 28, 2016. The outstanding principal and accrued interest on the notes shall automatically convert into company equity securities issued in a qualified transaction at a conversion rate carrying a 15% discount to the lowest price per share issued in a qualified transaction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 152 | |
+1.77% | 42.86B | |
+45.04% | 41.36B | |
+12.24% | 42.74B | |
-8.83% | 27.68B | |
+7.44% | 25.15B | |
-23.01% | 18.63B | |
+30.56% | 12.37B | |
-1.82% | 11.92B | |
+8.35% | 11.21B |
- Stock Market
- Equities
- AOLS Stock
- News Aeolus Pharmaceuticals, Inc.
- Aeolus Pharmaceuticals Inc. announced that it has received $1 million in funding from BVF Partners LP.